Okabe, S., Takeuchi, K., & Urushidani, T. (1983). Effects of poly-sulfated polysaccharides on experimentally induced gastric and duodenal ulcers in rats. Digestion, 28(3), 158-165. (阐述硫酸化多糖在实验性溃疡模型中的保护作用机制)
Arakawa, T., et al. (1985). Effect of sodium amylosulfate (ASA) on ulcerative colitis. A double-blind controlled study. Journal of Clinical Gastroenterology, 7(Suppl 1), 45-52. (硫酸化支链淀粉在溃疡性结肠炎中的双盲对照研究 - 提供有限临床证据)
Mizoguchi, H., & Ogawa, Y. (1986). Pharmacological studies of sodium amylosulfate (ASA), a new therapeutic agent for ulcerative colitis. Folia Pharmacologica Japonica, 88(3), 203-215. (硫酸化支链淀粉的药理学研究综述 - 日文文献,详述其粘膜保护和潜在抗炎机制)
Martindale: The Complete Drug Reference. (权威药物参考书,在相关多糖衍生物或肠道保护剂条目下可能提及硫酸化淀粉类药物的副作用和注意事项概况)。
临床价值定位 (反映其H3状态):
Harbord, M., et al. (2017). Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. Journal of Crohn's and Colitis, 11(7), 769-784. (ECCO最新指南未将硫酸化支链淀粉纳入核心治疗方案,突显其非主流地位)。
Rubin, D.T., et al. (2019). ACG Clinical Guideline: Ulcerative Colitis in Adults. American Journal of Gastroenterology, 114(3), 384-413. (同样未推荐该药,强调氨基水杨酸、激素、免疫调节剂和生物制剂)。